home / stock / cvac / cvac articles
U.S. stocks were higher, with the Nasdaq Composite gaining over 100 points on Monday. Shares of Spirit Airlines, Inc. (NYSE:SAVE) fell sharply duri...
Canadian Biotech company Acuitas Therapeutics and Germany-based CureVac NV (NASDAQ:CVAC) have settled Acuitas’ lawsuit ov...
CureVac N.V. (NASDAQ:CVAC) released interim data on Thursday, April 4, from studies it conducted on its seasonal influenza vaccine candidate. The ...
Shares of Compugen Ltd. (NASDAQ: CGEN) shares rose sharply during Tuesday’s session after Gilead announced an agreement with the company to ...
A German court has invalidated a patent central to CureVac N.V's (NASDAQ: CVAC) lawsuit against BioNTech SE (NASDAQ: BNTX) ...
U.S. stocks traded higher, with the Dow Jones index gaining around 150 points on Tuesday. Shares of bluebird bio, Inc. (NASDAQ: BLUE) shares fell ...
Biotech company Acuitas Therapeutics has filed a lawsuit in Virginia federal court against Germany-based CureVac SE (NASDAQ: CV...
Gainers Bionomics Limited (NASDAQ: BNOX) shares jumped 308% to $4.00 after the company announced the ATTUNE trial met its primary endpoint showing...
News, Short Squeeze, Breakout and More Instantly...
New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas Therapeutics First instance decision on validity of EP 3 708 668 B1 (split poly-A tail technology) scheduled for March 25, 2025, by European Patent Office in the context of the German patent ...
GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinations CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone pa...
Strategic restructuring includes a workforce reduction of approximately 30%, re-focusing on research, development, and innovation to create leaner and more agile organization Prioritization of high-value opportunities in oncology and other selected diseases, leveraging proprietary mRNA tec...